MedinCell stock
MEDCL.PAPARMedinCell S.A., HealthcareISIN FR0004065605
47Score 47 out of 100, Weak
Price and trend
80 / 100
Price history
−5.3% in one yearThe chart shows daily closes over 8 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Above the 200-day line: the price is 16% above it.
Since November 2026 the 50-day line has been above the 200-day line; the trend has turned up.
Overheated: the price has risen very quickly lately (RSI 77).
The price is 4.2% below its 52-week high. Largest decline in 8 years: 70% (January 2021 to August 2022).
Chart figures for advanced users
- SMA 50$27.93
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$27.66
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)77
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$22.43
- The lowest closing price of the last twelve months.
- Resistance$33.64
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- MedinCell S.A. belongs to the Biotechnology industry (France) and, with a market value of $1.16B, is number 177 of 289 companies in its industry on MEQIRI.
- In fiscal 2026 it reported revenue of $21.63M (down 23.6% year on year) and a loss of $34.67M.
- MEQIRI Score 47 out of 100 (Weak): rank 418 of 702 in Healthcare, median 53.
Show more
- Our model puts fair value at $38.73, with the price 17% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- More cash than debtCash $93.99M, financial debt $63.62M.
Weaknesses
- High debtDebt 18.74 times equity (latest quarter), Biotechnology median 0.09.Stability 31
- DilutionShare count up 63% since 2021.Capital allocation 18
- Loss-makingLoss of $34.67M over the last 12 months.Fundamentals 17
Its standout strength is technical analysis, while capital allocation and fundamentals hold the score back.
Daily figure as of 13 Nov 2026
How the score is calculatedScore overview
Score since yesterday from 48 to 47.
Fundamental quality fluctuates.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk high
How well MEQIRI warnsOne of the 30% with the highest crash risk among smaller stocks.
From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What drives the risk
- weak fundamentals
What lowers it
- price near its 52-week high
Valuation
Valuation signal
Modestly undervaluedIn our model the price counts as cheap below $27.66 and expensive above $64.55 (uncertainty high, based on the price swings of the past year).
Calculated with a cost of equity of 8.4%. At 9.4% the fair value would be $32.26, at 7.4% it would be $48.05.
Valuation metrics
From the cash-flow model alone; without earnings there is no industry value.
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In fiscal 2026, revenue fell 23.6% on the prior year. Revenue has grown strongly since 2019, at around 45% per year. From 2019 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2026: gross 100%, operating −131%, net −160%. Last 12 months: net −100%. From 2019 revenue is reported differently (for example gross instead of net), so earlier years are not comparable and not shown.
Debt & balance sheet
latest quarterDebt is elevated. Keep an eye on the interest burden and refinancing.
Earnings
- Next earnings
- 8 Dec 2026in 25 days
- Last reported
- 16 Jun 2026EPS reported −$0.50 (expected −$0.16)below expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- −$0.170.0%
- Revenue
- $42.14M0.0%
- Earnings per share
- $0.480.0%
- Revenue
- $64.43M0.0%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook confirmed
Share price after the results: −11.4%Partner sales of close to $300 million are expected for 2026 (Teva's initial guidance was $250 million to $280 million), with first royalties as early as Q4 2026.
“Teva's initial 2026 guidance is $250 million-$280 million, with $63 million already delivered in the first quarter of the year.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 16 Jun 2026 (fiscal Q4 2026), read by AI.
What happened at MedinCell
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
702 rated companies in Healthcare
- This company
- 47
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Biotechnology
The next larger and next smaller companies by market value
- KardiganKARD $1.26B44
- Rapport TherapeuticsRAPP $1.24B33
- Alpha Tau MedicalDRTS $1.24B42
- SavaraSVRA $1.2B33
- Structure TherapeuticsGPCR $1.14B31
- SpyGlass PharmaSGP $1.11B47
- MoonLake ImmunotherapeuticsMLTX $1.1B35
- InventivaIVA.PA $1.09B31
ETFs that hold MedinCell
Held by 11 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Amundi MSCI EMU Small Cap ESG Broad Transition UCITS ETF DISTLGWU | 0.17% | 0.40% | €580.62M |
| iShares MSCI EMU Small Cap UCITS ETFSXRJ | 0.12% | 0.58% | €838.19M |
| iShares Healthcare Innovation UCITS ETF2B78 | 0.11% | 0.40% | €1.5B |
Show 5 more
| Amundi MSCI Europe Small Cap ESG Broad Transition UCITS ETF DistX026 | 0.11% | 0.23% | €321.86M |
| iShares Ageing Population UCITS ETF2B77 | 0.10% | 0.40% | €813.42M |
| Xtrackers MSCI Europe Small Cap UCITS ETF 1CXXSC | 0.04% | 0.30% | €3.45B |
| UBS MSCI EMU Select Factor Mix UCITS ETF EUR accUIQN | 0.02% | 0.34% | €16.96M |
| State Street SPDR MSCI World Small Cap UCITS ETF (Acc)ZPRS | 0.01% | 0.45% | €1.54B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2026, period end 31 Mar 2026
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 30 Sep 2019)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.